Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€4.15 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.80B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.2
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership With JanssenA meaningful collaboration with Janssen supplies non-dilutive funding, development and commercialization expertise, and milestone/royalty upside. Structurally, such a partner de-risks late-stage development, improves regulatory and market access prospects, and supports future recurring revenue potential.
Proprietary Nanoparticle PlatformThe proprietary NBTXR3 nanoparticle platform targets radiosensitization and potential immune priming across indications. Platform-level IP and modality applicability enable multi-indication development, scalable pipeline expansion and durable product differentiation versus single-agent therapies, supporting long-term optionality.
Very High Reported Gross Margin In 2025A reported 100% gross margin in 2025 (driven by the revenue mix) suggests favorable underlying economics for collaboration/licensing income and low COGS for realized revenue. If sustained with recurring partner or royalty revenues, this margin profile provides strong operating leverage toward profitability as top line stabilizes.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates the company structurally relies on external financing to fund R&D and operations. Over the medium term this raises dilution risk, limits flexibility to scale trials or commercialization, and increases dependency on partner milestones or capital markets timing.
Negative Shareholders' Equity And Rising DebtNegative equity combined with increasing debt materially weakens the capital structure and reduces financial flexibility. Higher leverage elevates refinancing and covenant risk, raises the cost of capital, and constrains the company’s ability to self-fund commercialization or absorb clinical setbacks without dilutive financing or onerous terms.
Volatile, Inconsistent Revenue HistorySharp 2025 rebound after inconsistent prior years (and a negative 2024) signals revenues are timing- and milestone-driven rather than stable product sales. This volatility hampers forecasting, undermines repeatable cash generation, and makes it harder to demonstrate sustainable earnings power to support investment in commercialization.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €4.15 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.80B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 79 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---